Medline (NASDAQ:MDLN) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Medline (NASDAQ:MDLN) in a report released on Monday, Marketbeat reports. The firm issued a buy rating and a $50.00 price target on the stock.

A number of other brokerages have also recently commented on MDLN. Barclays started coverage on shares of Medline in a research report on Monday. They issued an “overweight” rating and a $50.00 target price on the stock. Wolfe Research started coverage on Medline in a report on Monday. They issued an “outperform” rating and a $47.00 price objective on the stock. Redburn Partners set a $42.00 target price on Medline in a report on Monday. Mizuho started coverage on Medline in a research report on Monday. They set an “outperform” rating and a $48.00 price target on the stock. Finally, Wall Street Zen upgraded Medline to a “hold” rating in a research report on Saturday, January 10th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Medline has a consensus rating of “Moderate Buy” and an average price target of $46.70.

Medline Stock Up 1.3%

Shares of NASDAQ:MDLN opened at $43.41 on Monday. Medline has a one year low of $34.89 and a one year high of $45.50.

Insider Activity

In other news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the completion of the transaction, the insider directly owned 4,806,160 shares of the company’s stock, valued at $136,350,759.20. The trade was a 55.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Andrew J. Mills purchased 2,586,206 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was purchased at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the purchase, the director owned 2,586,206 shares in the company, valued at approximately $74,999,974. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.